{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"}],"units":"Participants"}],"description":"Descriptive analysis based on number of patients alive at database lock (1-May-2020).","groups":[{"description":"Relapsed or refractory myeloma patients.","id":"OG000","title":"AUTO2"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All patients who receive at least 1 dose (complete or partial dose) of AUTO2 therapy","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"Participants"}